Xinping Zhou

10PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyMedical infection agents (incl. prions)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 19, 2026
Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot Study.

|Feb 03, 2025
Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts.

Gaixiang Xu, Xingnong Ye, Yudi Zhang

|Apr 17, 2024
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells.

Shuanghong Zhu, Yingwan Luo, Kongfei Li

|Nov 21, 2023
Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact.

Wei Wang, Yudi Zhang, Wenli Yang

|Jul 26, 2023
Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia.

Xinping Zhou, Wei Lang, Chen Mei

|Dec 14, 2022
15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.

Chen Mei, Li Ye, Yanling Ren

Pageof 2

Frequent Collaborators

7 joint publications

Yanling Ren

6 joint publications

Hongyan Tong

5 joint publications

Jie Jin

4 joint publications

Chen Mei